- Home
- KBR vs ITCI Comparison
KBR vs ITCI Comparison
Compare KBR & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBR
- ITCI
- Stock Information
- Founded
- KBR 1901
- ITCI 2002
- Country
- KBR United States
- ITCI United States
- Employees
- KBR N/A
- ITCI N/A
- Industry
- KBR Military/Government/Technical
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- KBR Industrials
- ITCI Health Care
- Exchange
- KBR Nasdaq
- ITCI Nasdaq
- Market Cap
- KBR 8.3B
- ITCI 8.0B
- IPO Year
- KBR 2006
- ITCI N/A
- Fundamental
- Price
- KBR $60.84
- ITCI $73.56
- Analyst Decision
- KBR Strong Buy
- ITCI Strong Buy
- Analyst Count
- KBR 9
- ITCI 11
- Target Price
- KBR $76.00
- ITCI $93.55
- AVG Volume (30 Days)
- KBR 745.0K
- ITCI 465.2K
- Earning Date
- KBR 10-31-2024
- ITCI 10-31-2024
- Dividend Yield
- KBR 0.99%
- ITCI N/A
- EPS Growth
- KBR N/A
- ITCI N/A
- EPS
- KBR 1.48
- ITCI N/A
- Revenue
- KBR $7,173,000,000.00
- ITCI $564,526,000.00
- Revenue This Year
- KBR $9.66
- ITCI $46.60
- Revenue Next Year
- KBR $13.63
- ITCI $37.06
- P/E Ratio
- KBR $41.17
- ITCI N/A
- Revenue Growth
- KBR 7.22
- ITCI 54.31
- 52 Week Low
- KBR $49.37
- ITCI $45.50
- 52 Week High
- KBR $69.50
- ITCI $84.89
- Technical
- Relative Strength Index (RSI)
- KBR 28.61
- ITCI 46.57
- Support Level
- KBR $66.61
- ITCI $71.75
- Resistance Level
- KBR $67.50
- ITCI $76.34
- Average True Range (ATR)
- KBR 1.31
- ITCI 1.75
- MACD
- KBR -0.78
- ITCI -0.02
- Stochastic Oscillator
- KBR 3.62
- ITCI 28.33
About KBR KBR Inc.
KBR (formerly Kellogg, Brown & Root) is global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: government solutions and sustainable technology solutions. KBR has operations in over 30 countries, and employs approximately 34,000 people. The firm generated $7 billion in revenue in 2023.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.